Kura Oncology, Inc. (KURA)
A
Pipeline Grade
Financial Position (from SEC Filings)
$39.1M
Cash & Equivalents
$85.9M
Quarterly Burn Rate
1 mo
Est. Cash Runway
$909M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
ZIFTOMENIB
KOMZIFTI |
APPROVED | Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, With Appropriate Mutations, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia, With NPM1 Mutations, Advanced Malignant Neoplasm, Advanced Solid Tumor, AML, AML With Mutated NPM1, Clear Cell Renal Cell Carcinoma (ccRCC), Colorectal Cancer (CRC), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Cell Tumors, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Tumor, Malignant, Hematologic Malignancy, HNSCC, HRAS Gene Mutation, HRAS Mutant Tumor, HRAS Mutations or Peripheral T Cell Lymphoma (PTCL), KMT2A-rearranged, KMT2Ar, Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leuk |
Upcoming Catalysts
No upcoming catalysts detected for this company.